Human medicines European public assessment report (EPAR): Truqap, capivasertib, Date of authorisation: 17/06/2024, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Tyverb, lapatinib, Date of authorisation: 10/06/2008, Revision: 38, Status: Authorised

Human medicines European public assessment report (EPAR): Sunosi, solriamfetol, Date of authorisation: 16/01/2020, Revision: 10, Status: Authorised

Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) – July 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, from 23 July 2025, 10:00 (CEST) to 23 July 2025, 11:30 (CEST)

Human medicines European public assessment report (EPAR): Galafold, migalastat, Date of authorisation: 25/05/2016, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Rotarix, rotavirus vaccine, live, Date of authorisation: 21/02/2006, Revision: 43, Status: Authorised

Questions and answers on the outcome of assessment on use of Revolade in treatment of severe aplastic anaemia in children

New product information wording: extracts from PRAC recommendations on signals adopted at the 7-10 July 2025 PRAC

Human medicines European public assessment report (EPAR): Piqray, alpelisib, Date of authorisation: 27/07/2020, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Fanskya, Mozafancogene autotemcel, Status: Application withdrawn